Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.
The recursive least-squares (RLS) adaptive filter is an appealing choice in many system identification problems. The main reason behind its popularity is its fast convergence rate. However, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback